Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in ...

Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy.The ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

DelveInsight's“ Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ ...

Overview of the Market  The global Cystic Fibrosis Market is valued at USD 10.3 Billion in 2024 and is projected to reach a ...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, ...

In ‘Culture Club’, Melanie Oliveiro examines a children’s book with a difference, ‘The Adventure Jar’, an illustrated story ...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance ...

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...